Teva announced it will buy Tevas Pharmaceuticals for $5 billion on Monday, and that it plans to pay $2.4 billion in cash for the stock.Teva shares fell 2.7% after the deal was announced.Tevas CEO Andrew Kress said the company will continue to focus on its primary focus, including expanding the value of its patient-centered care […]

Continue Reading...